RU2014133501A - Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением - Google Patents

Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением Download PDF

Info

Publication number
RU2014133501A
RU2014133501A RU2014133501A RU2014133501A RU2014133501A RU 2014133501 A RU2014133501 A RU 2014133501A RU 2014133501 A RU2014133501 A RU 2014133501A RU 2014133501 A RU2014133501 A RU 2014133501A RU 2014133501 A RU2014133501 A RU 2014133501A
Authority
RU
Russia
Prior art keywords
orgal
delivery
latanoprost
bimatoprost
treating
Prior art date
Application number
RU2014133501A
Other languages
English (en)
Other versions
RU2664686C2 (ru
Inventor
Майкл Р. РОБИНСОН
Джэймс А. БЁРКЕ
Хуй Лю
Вернер С. ОРИЛЛА
Лон Т. СПЭЙДА
Скотт УИТКАП
Алазар Н. ГЕБРЕМЕСКЕЛ
Патрик М. ХЬЮС
Кунь СЮЙ
Марианна М. ДО
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2014133501A publication Critical patent/RU2014133501A/ru
Application granted granted Critical
Publication of RU2664686C2 publication Critical patent/RU2664686C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ лечения повышенного внутриглазного давления, включающий стадию внутрикамерного введения пациенту с повышенным внутриглазным давлением вплотную к трабекулярной сети имплантата с замедленным высвобождением, выполненного в форме стержня, содержащего биоразлагаемый полимерный матрикс и латанопрост или биматопрост, при этом имплантат содержит от примерно 10 до примерно 50 масс.% латанопроста или биматопроста и от примерно 50 до примерно 90 масс.% биоразлагаемого полимерного матрикса, причем имплантат высвобождает терапевтически эффективные количества латанопроста или биматопроста на протяжении периода времени от примерно 10 дней до примерно 120 дней.

Claims (1)

  1. Способ лечения повышенного внутриглазного давления, включающий стадию внутрикамерного введения пациенту с повышенным внутриглазным давлением вплотную к трабекулярной сети имплантата с замедленным высвобождением, выполненного в форме стержня, содержащего биоразлагаемый полимерный матрикс и латанопрост или биматопрост, при этом имплантат содержит от примерно 10 до примерно 50 масс.% латанопроста или биматопроста и от примерно 50 до примерно 90 масс.% биоразлагаемого полимерного матрикса, причем имплантат высвобождает терапевтически эффективные количества латанопроста или биматопроста на протяжении периода времени от примерно 10 дней до примерно 120 дней.
RU2014133501A 2009-03-25 2014-08-15 Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением RU2664686C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/411,250 US20100247606A1 (en) 2009-03-25 2009-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US12/411,250 2009-03-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011140433/15A Division RU2532333C2 (ru) 2009-03-25 2010-03-25 Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний

Publications (2)

Publication Number Publication Date
RU2014133501A true RU2014133501A (ru) 2016-03-10
RU2664686C2 RU2664686C2 (ru) 2018-08-21

Family

ID=42326990

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2011140433/15A RU2532333C2 (ru) 2009-03-25 2010-03-25 Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний
RU2014133501A RU2664686C2 (ru) 2009-03-25 2014-08-15 Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2011140433/15A RU2532333C2 (ru) 2009-03-25 2010-03-25 Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний

Country Status (13)

Country Link
US (1) US20100247606A1 (ru)
EP (1) EP2411013B1 (ru)
JP (2) JP2012521997A (ru)
KR (4) KR20180108883A (ru)
CN (1) CN102497865A (ru)
AU (3) AU2010229891A1 (ru)
BR (1) BRPI1012324A2 (ru)
CA (1) CA2756065A1 (ru)
IL (1) IL215205A0 (ru)
MX (1) MX2011009901A (ru)
NZ (1) NZ595294A (ru)
RU (2) RU2532333C2 (ru)
WO (1) WO2010111449A1 (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
DK3085358T3 (en) * 2010-01-22 2018-02-05 Allergan Inc INTRAKAMERAL IMPLANTS WITH DEPOT PREPARATION
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
ES2634551T3 (es) 2010-04-03 2017-09-28 Praful Doshi Métodos para revestir una lente de contacto
WO2012012546A2 (en) * 2010-07-21 2012-01-26 Allergan, Inc. METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
JP2013534251A (ja) * 2010-08-17 2013-09-02 アラーガン インコーポレイテッド 角膜混濁を治療するためのｅｐ２またはｅｐ４アゴニスト
WO2012149278A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
PE20142083A1 (es) 2011-09-16 2014-12-30 Fovea Pharmaceuticals Derivados de anilina, su preparacion y su aplicacion terapeutica
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
EP2570402A1 (en) * 2011-09-16 2013-03-20 Fovea Pharmaceuticals Bi-aryl derivatives, their preparation and their therapeutic application
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
US9283231B2 (en) 2013-01-31 2016-03-15 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure of glaucoma
CN104055695B (zh) * 2013-03-22 2016-12-28 深圳市绿蛙生物科技有限公司 中药型快干消毒护手霜及其制备方法
ES2834964T3 (es) * 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
EP3656375A1 (en) * 2013-04-12 2020-05-27 Allergan, Inc. Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
US9492316B2 (en) 2013-10-31 2016-11-15 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
CN105266952A (zh) * 2014-07-09 2016-01-27 首都医科大学附属北京同仁医院 一种抗青光眼手术中所用防术后结膜粘连的器材
CN106604695B (zh) * 2014-09-06 2018-10-23 整体生物系统有限责任公司 用于在眼中实现持续药物释放的方法和生物相容性组合物
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
JP7430529B2 (ja) * 2016-09-23 2024-02-13 インセプト・リミテッド・ライアビリティ・カンパニー 前房内薬物送達デポ
TW201907907A (zh) * 2017-07-17 2019-03-01 新加坡商福溪生技有限公司 用於輸送活性劑的微粒調配物
RU2685499C1 (ru) * 2018-07-19 2019-04-18 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения прогрессирующей миопии у детей с выявленным привычно-избыточным напряжением аккомодации
US20200069696A1 (en) * 2018-08-30 2020-03-05 Yunxiang Liu Ophthalmic injectable formulation preparing and oculopathy treating and preventing
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
BR112021015567A2 (pt) * 2019-02-08 2021-10-26 Ohio State Innovation Foundation Substitutos de vítreos de liberação de antioxidantes e usos dos mesmos
AU2021215929A1 (en) 2020-02-06 2022-08-04 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2021231977A1 (en) * 2020-05-15 2021-11-18 Georgia Tech Research Corporation Methods and compositions for reducing intraocular pressure
JP2023529168A (ja) * 2020-06-03 2023-07-07 グラウコス コーポレイション Ｒｈｏキナーゼ阻害剤放出インプラントおよび関連する使用方法
AU2022215614A1 (en) * 2021-02-05 2023-09-14 Jenivision Inc. Compositions and methods for periorbital administration of ep2 receptor agonists
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT252264B (de) * 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3749776A (en) * 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US4403353A (en) * 1981-06-25 1983-09-13 Tennant Jerald L Anterior chamber implant lens
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CA2554424A1 (en) * 2004-01-26 2005-08-11 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7476747B2 (en) * 2005-03-10 2009-01-13 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2602577C (en) * 2005-10-18 2015-03-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
KR20080082618A (ko) * 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
CA2637602C (en) * 2006-01-17 2014-09-16 Forsight Labs, Llc Drug delivery treatment device
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
EP2364707B1 (en) * 2006-08-07 2013-04-03 Bausch & Lomb Incorporated Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
AU2008208042B2 (en) * 2007-01-25 2014-02-27 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
KR20100101097A (ko) * 2007-11-09 2010-09-16 알러간, 인코포레이티드 프로스타글란딘 활성을 갖는 치환된 사이클로펜탄
AU2009236356A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
WO2009143288A1 (en) * 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
DK3085358T3 (en) * 2010-01-22 2018-02-05 Allergan Inc INTRAKAMERAL IMPLANTS WITH DEPOT PREPARATION

Also Published As

Publication number Publication date
BRPI1012324A2 (pt) 2016-03-15
NZ595294A (en) 2013-11-29
AU2010229891A1 (en) 2011-10-20
RU2011140433A (ru) 2013-04-27
US20100247606A1 (en) 2010-09-30
KR20160120800A (ko) 2016-10-18
EP2411013B1 (en) 2020-08-19
AU2016231616A1 (en) 2016-10-20
AU2018211329A1 (en) 2018-08-23
KR20120006998A (ko) 2012-01-19
MX2011009901A (es) 2011-11-18
CN102497865A (zh) 2012-06-13
KR20180108883A (ko) 2018-10-04
JP2012521997A (ja) 2012-09-20
WO2010111449A1 (en) 2010-09-30
EP2411013A1 (en) 2012-02-01
CA2756065A1 (en) 2010-09-30
RU2532333C2 (ru) 2014-11-10
RU2664686C2 (ru) 2018-08-21
JP2015007117A (ja) 2015-01-15
KR20170064556A (ko) 2017-06-09
IL215205A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
RU2014133501A (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
DE602005013244D1 (de) Pharmazeutische zusammensetzungen für die kontroll
EP2349367A4 (en) MODIFIED SILK FILMS WITH GLYCEROL
JP2013526572A5 (ru)
WO2010062523A3 (en) Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
MX2021004707A (es) Nuevos compuestos antihelminticos.
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
CA3010374A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
JP2012521997A5 (ru)
CL2012000317A1 (es) Composicion agricola que comprende una mesocapsula con una caparazon polimerica y un ingrediente agricola activo incluido dentro de la caparazon polimerica; metodo para controlar insectos, acaridos y enfermedades de plantas o hierbas malas; metodo para sintetizar dicha mesocapsula.
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
NZ602540A (en) Bioadhesive compositions of local anaesthetics
NZ602538A (en) Thermogelling anaesthetic compositions
TW200833376A (en) Sustained-release composition and method for producing the same
HRP20171330T1 (hr) Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
MX2010007672A (es) Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
UA114088C2 (xx) Лікарська композиція з пролонгованим вивільненням для ін'єкцій
PH12017500570A1 (en) Methods for the treatment of peri-implantitis
NZ608406A (en) Use of storage stable viscous phospholipid depot to treat wounds